

Figure S1
Foureau et al.




Figure S1: Cumulative analysis of CD8 Foxp3⁺/-prevalence in all murine melanoma screened for rhIL-2 treatment responsiveness. Frequencies of CD8 Foxp3⁺ T cells (A, C, E.; e.g. left panel) and their Foxp3⁻ counterparts (B, D, F.; e.g. right panel) among lymphocytes isolated from spleen, peripheral blood mononuclear cells (PBMCs), and axillary-brachial lymph nodes (AB.LNs) from B16-F1, B16-BL6, JB/MS, MCA-205, JB/RH and B16-F10 tumor-bearing C57BL/6 mice treated with high dose rhIL-2 (50,000U) *s.q.* or *i.p.* Data are expressed as mean percentage CD8 Foxp3⁺ T cells (or Foxp3⁻) relative to total lymphocyte population ± SEM. n=6 independent experiments, *p<0.05 versus untreated, **p<0.01 versus untreated.